MedTrace Logo

Innovative Technologies for the Treatment of Pulmonary and Heart Failure

NCT05090930 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-10-25

No results posted yet for this study

Summary

The purpose of the program. Formulation of new treatments for heart and pulmonary failure through using organ-replacing technologies.

Formulation of a clinical protocol and implementation of treatment methods into clinical practice heart and pulmonary failure using organ-replacing technologies.

New methods were created for rehabilitating the function of affected organs after implantation of the LVAD, a total artificial heart, an extracorporeal life-sustaining system will be of great importance, both for Kazakhstan and for states with similar problems of donor organ deficiency, will also improve the effectiveness of surgical treatment and reduce the level of complications and mortality of patients on the extracorporeal life-sustaining system and septic patients.

Conditions

  • Cardiogenic Shock
  • Ventricular Arrythmia
  • Cardiac Arrest With Successful Resuscitation
  • Sepsis
  • Multiple Organ Failure
  • Pulmonary Failure
  • Decompensated Heart Failure
  • Acute Heart Failure

Interventions

DEVICE

HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection

HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated

DEVICE

CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber

CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated

Sponsors & Collaborators

  • Ministry of Education and Science, Republic of Kazakhstan

    collaborator OTHER_GOV

  • National Research Center for Cardiac Surgery, Kazakhstan

    lead OTHER

Principal Investigators

  • Yuri Pya, PhD, MD · National research Center for Cardiac Surgery JSC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-07-01
Completion
2023-12-01

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05090930 on ClinicalTrials.gov